An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Retinitis Pigmentosa

In brief

This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.

Key facts

Study ID

NCT00661479

Run by

Allergan

People needed

21

Starts

2008-07-01

Expected to finish

2010-05-01

Last updated by the study team

2013-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Retinitis Pigmentosa in both eyes
• Visual acuity between 20/40 to count fingers

You may not qualify if…

• Growth of new blood vessels in the eye
• Any intraocular surgery or laser in either eye in the last 6 months prior to Screening visit or between the Screening visit and Day 1
• Any ocular disease that can interfere with diagnosis and or assessment of disease progression
• Significant near-sightedness
• HIV
• Female patients who are pregnant, nursing, or planning pregnancy

Where it is running

• Study site — Arlington, Texas, United States
• Study site — Paris, France
• Study site — Tübingen, Germany
• Study site — Coimbra, Portugal

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.